Jakafi, a medication for myelofibrosis, polycythemia vera, and graft-versus-host disease, has a significant cost. The list price for Jakafi can be approximately $22,000 for a 30-day supply, though actual out-of-pocket costs for patients vary based on insurance coverage, copay assistance programs, and other factors [1].
How much does a month of Jakafi cost?
A month's supply of Jakafi can cost around $22,000. This figure represents the list price, and patient expenses are often reduced through various financial assistance programs.
What financial assistance is available for Jakafi?
Incyte, the manufacturer of Jakafi, offers patient assistance programs. These programs aim to help eligible patients afford the medication. Details on eligibility and application processes for these programs are typically available through Incyte's patient support services [1].
How does Jakafi's cost compare to other myelofibrosis treatments?
The cost of Jakafi is comparable to other advanced therapies used for myelofibrosis. Treatment costs in this therapeutic area are generally high due to the complexity of the diseases and the innovative nature of the drugs.
When does Jakafi's patent expire?
Information regarding the specific patent expiry dates for Jakafi is detailed and can be tracked through specialized patent databases. DrugPatentWatch.com provides comprehensive data on drug patents and exclusivity periods, which is crucial for understanding when generic versions might become available [2].
Are there generic versions of Jakafi available?
As of current information, there are no generic versions of Jakafi available. The patent protection on the drug prevents generic competition until those patents expire.
What is the mechanism of action for Jakafi?
Jakafi is a Janus kinase (JAK) inhibitor, specifically targeting JAK1 and JAK2. These enzymes play a role in signaling pathways that are implicated in the development of myeloproliferative neoplasms and graft-versus-host disease. By inhibiting these kinases, Jakafi helps to reduce inflammation and symptoms associated with these conditions [3].